Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) reported third-quarter 2026 net product revenue of approximately $17.2 million, a more than fivefold increase from $3.3 million in the prior-year period, according to the company’s latest financial results. The performance was anchored by TONMYA, the company’s recently approved flagship medicine for fibromyalgia, which contributed $15 million in revenue, up 37% from the second quarter.
The commercial momentum extends beyond revenue. Total prescriptions rose 28% quarter over quarter to 16,375, with new prescriptions increasing 17% and refills climbing 56%. TONMYA coverage expanded to approximately 166 million lives, and Tonix increased its sales force to about 150 representatives. Those metrics suggest the company is successfully converting its approval into broader payer access and repeat use, a critical test for any newly launched chronic-care therapy.
Still, the bottom line remains under pressure. Tonix reported a net loss available to common stockholders of $53.3 million, or $2.89 per share, compared with a loss of $32 million, or $3.59 per share, a year earlier. The wider loss reflects the costs of scaling a commercial organization and advancing a clinical pipeline. The company ended the quarter with approximately $163 million in cash and cash equivalents and expects its resources, together with roughly $1.5 million in subsequent equity financing proceeds, to fund operations into early third-quarter 2027.
That runway matters because Tonix is not standing still. The company continues to advance the Phase 2 HORIZON study of TNX-102 SL for major depressive disorder, the planned Phase 2 TRAIL study of TNX-4800 for Lyme disease prevention, and an investigator-initiated Phase 2 study of TNX-1500 for kidney transplant rejection prevention. The latter two studies are expected to begin in the first quarter of 2027, with the TNX-4800 study pending final U.S. Food and Drug Administration agreement on its protocol.
The implications are twofold. First, TONMYA’s growth gives Tonix a commercial base that can support its central nervous system infrastructure, which also includes acute migraine products Zembrace SymTouch and Tosymra. Second, the pipeline—spanning CNS and immunology programs—offers optionality beyond fibromyalgia, but only if the company can fund it through key readouts. The cash guidance into early third-quarter 2027 leaves little room for missteps, making upcoming trial starts and prescription trends closely watched indicators.
For investors tracking the small-cap biotechnology space, Tonix’s quarter illustrates both the promise and the cost of transitioning from development to commercialization. Additional details are available in the full press release at https://ibn.fm/xRQdn, and ongoing updates can be found in the company’s newsroom at https://ibn.fm/TNXP. The announcement was distributed through TinyGems, part of the Dynamic Brand Portfolio at IBN, which provides corporate communications solutions and reaches audiences through social media distribution.


